Beta-blockers represent a cornerstone for the treatment of coronary artery disease (CAD). Their protective effect is based on the negative inotropic and chronotropic features, which have been tested in a large number of randomized controlled trials, both in patients with myocardial infarction (MI) and in those with stable angina, demonstrating a reduction of adverse cardiovascular events, a relief of symptoms and a reduction of myocardial ischemia However, considerable interpatient variability in response to β-blockers has been reported which indicates that a considerable proportion of β-blocker-treated patients do not achieve the warranted cardio protection with β- blockers. This highlights the importance of identifying biomarkers associated with variability in response to β-blockers to improve the current approach for β- blocker selection, which seems to be suboptimal. This study aims to study the effect of polymorphism in adrenergic beta receptors on beta-blocker response in Egyptian patients.
Study Type
OBSERVATIONAL
Enrollment
80
Ain Shams University Hospitals.
Cairo, Cairo Governorate, Egypt
Adrenergic receptors genes and blood pressure response to beta-blocker
Investigate the association of the adrenergic receptor polymorphisms with reduction in blood pressure (expressed in units of millimeters of mercury "mmHg" ) in the Egyptian patients with acute coronary syndrome on beta blocker therapy.
Time frame: Three months
Adrenergic receptors genes and heart rate response to beta-blocker
Investigate the association of the adrenergic receptor polymorphisms with reduction in heart rate (expressed as beats per minute "BPM" ) in the Egyptian patients with acute coronary syndrome on beta blocker therapy.
Time frame: Three months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.